CEO Harald Schnidar in the B&C Group podcast about protection for innovations and patent rights
In the B&C Group's podcast Über:Mut, Scarletred's CEO Harald Schnidar discusses together with Mariana Karepova, President of the Austrian Patent Office, the protection and potential of innovations in Austria.
New Study Shows Meaningful Results with Bimiralisib in Mycosis Fungoides Patients using Scarletred®Vision
Topical Bimiralisib, used in patients with the rare cutaneous form of T-cell lymphoma, known as Mycosis fungoides, and healthy patients, showed substantial results regarding cutaneous drug levels.
SCARLETRED Presenting at the 6th Dermatology Drug Development Summit in Boston
The 6th Dermatology Drug Development Summit for inflammatory skin diseases gives insight into novel therapeutics and patient-specific and alternative treatment options currently in clinical trials for various skin diseases.
BioJapan 2022: SCARLETRED Joins Innovative Companies at the Leading Life Science and Pharmaceutical Fair in Tokyo
The life science and pharmaceutical fair takes place October 11-14th to bring together innovative companies, customers, and investors. SCARLETRED is one of nine companies representing the Austrian Economic Chambers in Tokyo.
Presentation of data from our published paper “The mathematics of erythema” at the ÖGRO congress in Villach, Austria
Our published paper about machine learning and developing the SEV value will be presented at the ÖGRO annual congress in Villach, Austria, with our collaborator at the Landeskrankenhaus Graz, Dr. Richard Partl.
New Diagnostic Accuracy Study Assessing SARS-CoV-2 Rapid Antigen Detection Tests using Scarletred®Vision
A study, performed by the Medical University of Vienna, examined diagnostic accuracy of SARS-CoV-2 rapid antigen tests compared to RT-PCR as the gold standard based on different swab sites by using Scarletred®Vision.
SCARLETRED Discovery Program (DP): SaaS as our novel flagship service for industry clinical trials
The DP aims to collaborate with pharmaceutical and biotechnology companies by providing access to our customizable software Scarletred®Vision for exploratory or early-stage clinical studies at a more attractive price point.
Dermatology & disease management: An interview with an expert about the applications of SCARLETRED
In an interview, specialist Dr. Zikeli discusses the clinical characteristics of atopic dermatitis and why documentation using Scarletred®Vision is an optimal support for diagnosis and progress monitoring.
SCARLETRED at Round-Table Discussion of Börse Express about Life Science Industry in Austria
In the round table discussion of the leading financial domain Börse Express, Marinomed, Scarletred, PHH Rechtsanwälte, and EOSS Industries discussed the development and hurdles of Austrian life science start-ups.
The mathematics of erythema: Development of machine learning models for artificial intelligence assisted measurement and severity scoring of radiation induced dermatitis